USTR Initiates §301 Investigation into Germany's Pharmaceutical Underpayment Practices

USTR has opened a §301 investigation into Germany's persistent underpayment for innovative pharmaceutical products, alleging unreasonable or discriminatory policies that burden U.S. commerce. A public hearing and comment period have been announced as part of the proceeding.